Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies

Potent EMT and CSC Phenotypes Are Induced By Oncostatin-M in Pancreatic Cancer

(2017) Jacob M. Smigiel et al.   MOLECULAR CANCER RESEARCH

Loss of P53 Function Activates JAK2–STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, and Gemcitabine Resistance in Mice and Is Associated With Patient Survival

(2016) Sonja M. Wörmann et al.   GASTROENTEROLOGY

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

(2016) Andrea Wang-Gillam et al.   LANCET

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

(2016) Jesse M. Zaretsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Systemic Inflammatory Response and Elevated Tumour Markers Predict Worse Survival in Resectable Pancreatic Ductal Adenocarcinoma

(2016) Aino Salmiheimo et al.   PLoS One

Abstract 1336: Novel immunotherapeutic activity of JAK and PI3Kδ inhibitors in a model of pancreatic cancer

(2015) Holly K. Koblish et al.   CANCER RESEARCH

Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed

(2015) Herbert I. Hurwitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Host systemic inflammatory response influences outcome in pancreatic cancer

(2015) Clem W. Imrie   PANCREATOLOGY

TCGA data and patient-derived orthotopic xenografts highlight pancreatic cancer-associated angiogenesis

(2015) Jesse Gore et al.   Oncotarget

Resistance of Cancer Cells to Targeted Therapies Through the Activation of Compensating Signaling Loops

(2014) Viktoria Manstein et al.   Current Signal Transduction Therapy

Beyond first-line chemotherapy for advanced pancreatic cancer: An expanding array of therapeutic options?

(2014) Evan J Walker   WORLD JOURNAL OF GASTROENTEROLOGY

Pancreatic cancer cachexia: a review of mechanisms and therapeutics

(2014) Carlyn R. Tan et al.   Frontiers in Physiology

The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancer

(2012) Donald C. McMillan   CANCER TREATMENT REVIEWS

Ruxolitinib: The First FDA Approved Therapy for the Treatment of Myelofibrosis

(2012) J. Mascarenhas et al.   CLINICAL CANCER RESEARCH

Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib

(2012) J. Mascarenhas et al.   CURRENT MEDICINAL CHEMISTRY

Ruxolitinib for the treatment of myelofibrosis: its clinical potential

(2012) Srdan Verstovsek et al.   Therapeutics and Clinical Risk Management

A Prospective Comparison of the Prognostic Value of Tumor- and Patient-Related Factors in Patients Undergoing Potentially Curative Surgery for Pancreatic Ductal Adenocarcinoma

(2011) Nigel B. Jamieson et al.   ANNALS OF SURGICAL ONCOLOGY

Stat3/Socs3 Activation by IL-6 Transsignaling Promotes Progression of Pancreatic Intraepithelial Neoplasia and Development of Pancreatic Cancer

(2011) Marina Lesina et al.   CANCER CELL

Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer

(2011) Kristine H. Allin et al.   CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

(2010) A. Quintas-Cardama et al.   BLOOD